Furthermore, limited dilution and in vivo tumorigenic assays revealed that co‐administration of CAFs‐2 robustly promoted tumor formation and increased CSCs frequencies, but failed to induce similar effects in those LIFR‐depleted cancer cells (Figure 6M). The gene discussed is LIFR; the disease is cancer.